NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

"I think (imho) Car-T being the relative new kid on the block (and the street does like what they perceive as disruptive technologies) has potential long term. Will need to be refined and might only be nich as costs will always be a challenge."


Well, it certainly seems (seemed?) to like Car-T.

Why not NWBO?

That's the point I'm making.

Why the disparity? Why the difference in perception?

Why is the FDA hellbent on getting the Car-T's to approval?

Why are Kite and Juno not subject to massive shorting?

But others believe that the FDA’s decision to lift the suspension so quickly is another sign that it is allowing the development of Car-T to evolve too quickly. “They are trying to referee a game while the rules are still being written. And it appears to be causing some deaths that should have been avoided,” says one buyside biotech analyst.



Despite the FDA’s swift decision, some investors and analysts remain worried that its chemotherapy hypothesis is just that: a hypothesis. They fear that there could be some other reason, as yet unapparent, for the fatal build-up of toxicity. Others wonder whether Juno was right to alter the chemotherapy partway through the trial. “I just don’t know, and I don’t think they really know either,” says Maxim Jacobs, a healthcare analyst at Edison. “I don’t know that you can rush to blame the chemotherapy.
“If this had happened at Genentech back in the day, they would probably have spent two years looking into this — not a week,” he says, referring to the biotech company set up to explore genetic medicine in 1976.



“I’m really surprised with how quickly the FDA has let all this go through,” says Mr Jacobs, making a criticism that is rarely levelled at a regulator that has a reputation for being cumbersome. “I feel if this were another treatment that were not so hot and in the news, then they would still be trying to work out the risks.”

Above quotes from:-

http://www.ft.com/cms/s/0/b5ce3750-492c-11e6-8d68-72e9211e86ab.html#axzz4KiKqTXrB